(Reuters) - Gilead Sciences Inc (O:GILD) reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.
Remdesivir brought in $873 million in the third quarter ended Sept. 30, below analysts' estimates of $960 million, according to Refinitiv IBES data.
Remdesivir, given intravenously, won formal U.S. approval last week, but the drug has been available under an FDA emergency use authorization since May.